Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocolXiangdong Cheng, Yunli Zhang, Jiuwei Cui et al.|BMC Cancer|2021Cited by 14
Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trialYu Pengfei, Xiangdong Cheng, Yian Du et al.|Journal of Clinical Oncology|2023Cited by 1
A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.Yu Pengfei, Xiangdong Cheng, Yian Du et al.|Journal of Clinical Oncology|2022Cited by 0
Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.Yu Pengfei, Xiangdong Cheng, Yian Du et al.|Journal of Clinical Oncology|2023Cited by 0